How to perform a successful drug-coated balloon angioplasty? Tips and tricks

Catheter Cardiovasc Interv. 2023 Dec;102(7):1238-1257. doi: 10.1002/ccd.30851. Epub 2023 Nov 10.

Abstract

Drug-coated balloons (DCB) offer an excellent alternative to stents as the antiproliferative drugs are delivered via balloons and hence there is no permanent implant of metal or polymer. This rationale applies perfectly in in-stent restenosis (ISR) as we want to avoid another layer of metal in a previously failed stent. However, their use has also been extended to de novo lesions especially in patients and lesion subsets where stents are not ideal. There is an increased desire toward expanding this further and studies are now being done which are testing DCB in large-caliber vessels. As the use of DCB is escalating, we felt the importance of writing this article whereby we aim to provide important tips and tricks when using DCB especially for the operators who are in the early phase or have the desire of embarking this technology. From our experience, the DCB-angioplasty substantially differs on several aspects from DES-angioplasty. We have provided several case bases examples including algorithm when using DCB in ISR and de novo lesions.

Keywords: BALA-balloon angioplasty; BALD-balloon; SRES-stent restenosis; drug coated/eluting.

Publication types

  • Review

MeSH terms

  • Angioplasty, Balloon* / adverse effects
  • Angioplasty, Balloon, Coronary* / adverse effects
  • Coated Materials, Biocompatible
  • Coronary Restenosis* / diagnostic imaging
  • Coronary Restenosis* / etiology
  • Coronary Restenosis* / therapy
  • Drug-Eluting Stents*
  • Humans
  • Paclitaxel
  • Stents
  • Treatment Outcome

Substances

  • Coated Materials, Biocompatible
  • Paclitaxel